The magnitude of therapeutic success correlates with type of venom, duration of therapy, and venom dose. Adult-onset MIS and/or a BTC > 20 μg/L is a significant, albeit not the strongest determinant for VIT failure. According to its odds ratio, ACE inhibitor therapy appears to be associated with the highest risk for VIT failure.
A565 patients in the UK. Methods: Moderate to severe PsO patients in the UK Hospital Treatment Insights (HTI) database with 1-year wash-out prior to first dispense, who completed induction and were on continued maintenance treatment during 1-year follow-up were included. We used two consecutive maintenance average daily doses ≥ 30% or ≥ 10% higher than indicated in the UK Summary of Product Characteristics (SPC) to assess above-label dose and estimated percentage of patients on above-label dose, mean time on above-label dose and extra costs per patient associated with above-label use relative to on-label use of biologics over the 1-year of follow-up period. Results: The final eligible sample included 362 PsO patients (adalimumab (
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.